Enhanced Compositions and Methods for Hepatic Disease Treatment

Improved pharmaceutical compositions and methods for treating hepatic diseases and disorders, enhancing therapeutic efficacy, stability, and patient compliance.

The original patent disclosed compositions and methods for treating hepatic disorders, particularly hepatitis C, via toll-like receptor (TLR) ligands. However, the patent's limitations included the need for improved stability, efficacy, and patient compliance. The new inventive concept addresses these limitations by introducing specific buffer systems, optimized formulations, and adapted administration methods.

The enhanced compositions comprise a TLR ligand that activates at least one or more TLRs or Nod-like receptors (NLRs), and a buffer selected from phosphate, citrate, or acetate, which improves the stability of the composition. The method for treating hepatitis C involves administering a pharmaceutical composition comprising a lysate and/or cell wall extract from a Gram-positive bacterium, which activates at least one or more TLRs or NLRs, and a buffer, to enhance therapeutic efficacy. The system for treating hepatic disorders is adapted for oral administration, improving patient compliance. Additionally, the composition's buffer is present in an optimized amount ranging from 0.1% to 5% by weight, ensuring an optimal therapeutic effect.

The new claims introduce specific buffer systems, optimized formulations, and adapted administration methods, which are not disclosed in the original patent. The inventive step lies in the selection of specific buffers and their optimized amounts, as well as the adaptation of the composition for oral administration, resulting in improved stability, efficacy, and patient compliance.

Alternative embodiments may include different buffer systems, such as tris or glycine, or varying the amount of buffer in the composition. Variations may also include using different Gram-positive bacteria or modifying the administration method, such as injectable or topical formulations.

The enhanced compositions and methods have significant commercial potential in the treatment of hepatic diseases and disorders, particularly hepatitis C. The target market includes pharmaceutical companies, research institutions, and healthcare providers, with potential applications in the development of new treatments and therapies.